Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald increased their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective for the company.

Vanda Pharmaceuticals Trading Up 3.0 %

Shares of NASDAQ VNDA opened at $5.09 on Monday. The stock has a fifty day simple moving average of $4.80 and a two-hundred day simple moving average of $5.26. Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The firm has a market cap of $296.80 million, a price-to-earnings ratio of -18.18 and a beta of 0.77.

Insider Buying and Selling

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.90% of the stock is currently owned by insiders.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds have recently made changes to their positions in VNDA. Barclays PLC raised its position in Vanda Pharmaceuticals by 128.2% in the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after purchasing an additional 86,677 shares during the period. Geode Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock worth $6,689,000 after buying an additional 94,870 shares during the period. ClearAlpha Technologies LP lifted its stake in shares of Vanda Pharmaceuticals by 50.0% in the 3rd quarter. ClearAlpha Technologies LP now owns 60,000 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 20,000 shares during the last quarter. Verition Fund Management LLC boosted its holdings in Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 2,927 shares during the period. Finally, BNP Paribas Financial Markets grew its position in Vanda Pharmaceuticals by 1,184.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 57,393 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.